Biodesix (BDSX) Enterprise Value (2019 - 2026)

Biodesix (BDSX) has 8 years of Enterprise Value data on file, last reported at -$25.6 million in Q1 2026.

• Quarterly Enterprise Value fell 45.27% year-over-year to -$25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.6 million (down 45.27% YoY) and the FY2025 annual result came in at -$19.0 million, up 27.65% from the prior year.
• Enterprise Value slipped to -$25.6 million in Q1 2026, from -$19.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$11.5 million in Q1 2024 to a low of -$43.1 million in Q4 2022.
• A 5-year average of -$23.4 million and a median of -$20.7 million in 2025 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 70.36% — and 2024, when it sank 142.51%.
• Tracing BDSX's Enterprise Value over 5 years: stood at -$43.1 million in 2022, then soared by 39.0% to -$26.3 million in 2023, then climbed by 0.15% to -$26.2 million in 2024, then rose by 27.65% to -$19.0 million in 2025, then tumbled by 34.68% to -$25.6 million in 2026.
• The last three Enterprise Value figures came in at -$25.6 million (Q1 2026), -$19.0 million (Q4 2025), and -$16.6 million (Q3 2025), per Business Quant data.